Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort

• Status: Completed
• Trial end date: 2021-05-28
• Target enrollment: 0
• Participant gender: All

Summary

The coronavirus disease 2019 (COVID-19) viral pneumonia is now a worldwide pandemic caused by the Severe acute respiratory virus coronavirus 2 (SARS-CoV-2). The number of cases, and associated mortality has increased dramatically since the first cases in Wuhan, China in December 2019 . To date, no specific treatment has been proven to be effective for COVID-19. Treatment is currently mainly supportive, with in particular mechanical ventilation for the critically ill patients (6.1% in a series of 1099 cases in China). Novel therapeutic approaches are in acute need. In this context, the therapeutic potential associated with convalescent plasma needs to be explored.

The objective of COVIPLASM trial (a nested trial in the CORIMUNO-19 COHORT) is to study the efficacy of convalescent plasma to treat SARS-COV2 infected patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: Etablissement Français du Sang

Criteria

Inclusion Criteria:

• Patients included in the CORIMUNO-19 cohort

• Onset of COVID19 functional signs <8 days (plasma transfusion may occur up to day 10 of onset)

• Mild severity as described in the WHO scale

Exclusion Criteria:

• Pregnancy

• Current documented and uncontrolled bacterial infection.

• Prior severe (grade 3) allergic reactions to plasma transfusion